激发针对 LKB1 突变肿瘤的研究。
Energizing the search to target LKB1-mutant tumors.
机构信息
Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
出版信息
Cancer Discov. 2013 Aug;3(8):843-5. doi: 10.1158/2159-8290.CD-13-0296.
Abstract
LKB1 is the third most frequently mutated gene in non-small cell lung cancer and serves as a master regulator of cell metabolism and polarity across a variety of model organisms. Recent studies are beginning to identify therapeutics that exploit defects associated with LKB1 loss. The work presented here by Liu and colleagues shows that deoxythymidylate kinase is a new potential target in LKB1-deficient tumors and highlights the possibility of a new therapeutic option for this subset of patients with cancer.
摘要
LKB1 是在非小细胞肺癌中突变频率第三高的基因，是多种模型生物中细胞代谢和极性的主调控因子。近期的研究开始鉴定利用与 LKB1 缺失相关缺陷的治疗方法。刘等人在这里的工作表明，脱氧胸苷激酶是 LKB1 缺陷肿瘤中的一个新的潜在靶点，并强调了为这部分癌症患者提供一种新的治疗选择的可能性。
相似文献
1
Energizing the search to target LKB1-mutant tumors.激发针对 LKB1 突变肿瘤的研究。
Cancer Discov. 2013 Aug;3(8):843-5. doi: 10.1158/2159-8290.CD-13-0296.
2
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.代谢和功能基因组研究鉴定脱氧胸苷酸激酶为 LKB1 突变型肺癌的靶点。
Cancer Discov. 2013 Aug;3(8):870-9. doi: 10.1158/2159-8290.CD-13-0015. Epub 2013 May 28.
3
LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.LKB1 在肺癌发生中的作用：一种丝氨酸/苏氨酸激酶作为肿瘤抑制因子。
Protein Cell. 2011 Feb;2(2):99-107. doi: 10.1007/s13238-011-1021-6. Epub 2011 Mar 5.
4
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.LKB1 活性对非小细胞肺癌对 PI3K/mTOR 抑制敏感性的影响。
J Thorac Oncol. 2019 Jun;14(6):1061-1076. doi: 10.1016/j.jtho.2019.02.019. Epub 2019 Feb 27.
5
The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC.AMPK 相关激酶 SIK1 和 SIK3 介导 LKB1 在 NSCLC 中的关键肿瘤抑制作用。
Cancer Discov. 2019 Nov;9(11):1606-1627. doi: 10.1158/2159-8290.CD-18-1261. Epub 2019 Jul 26.
6
WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.WEE1 激酶抑制剂 AZD1775 在 LKB1 缺陷型非小细胞肺癌中有临床前疗效。
Cancer Res. 2017 Sep 1;77(17):4663-4672. doi: 10.1158/0008-5472.CAN-16-3565. Epub 2017 Jun 26.
7
CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.CPS1维持KRAS/LKB1突变型肺癌细胞中的嘧啶库和DNA合成。
Nature. 2017 Jun 1;546(7656):168-172. doi: 10.1038/nature22359. Epub 2017 May 24.
8
LKB1 promotes metabolic flexibility in response to energy stress.LKB1 促进代谢灵活性以应对能量应激。
Metab Eng. 2017 Sep;43(Pt B):208-217. doi: 10.1016/j.ymben.2016.12.010. Epub 2016 Dec 26.
9
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in -Mutant Lung Adenocarcinoma.LKB1 和 KEAP1/NRF2 通路协同促进 - 突变型肺腺癌的代谢重编程和增强的谷氨酰胺依赖性。
Cancer Res. 2019 Jul 1;79(13):3251-3267. doi: 10.1158/0008-5472.CAN-18-3527. Epub 2019 Apr 30.
10
Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.免疫组织化学检测 LKB1 缺失是 KRAS 突变型肺腺癌中更具侵袭性生物学行为的生物标志物。
Clin Cancer Res. 2015 Jun 15;21(12):2851-60. doi: 10.1158/1078-0432.CCR-14-3112. Epub 2015 Mar 3.
引用本文的文献
1
Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer.解析STK11/LKB1在非小细胞肺癌中的作用
Cureus. 2022 Jan 10;14(1):e21078. doi: 10.7759/cureus.21078. eCollection 2022 Jan.
本文引用的文献
1
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.代谢和功能基因组研究鉴定脱氧胸苷酸激酶为 LKB1 突变型肺癌的靶点。
Cancer Discov. 2013 Aug;3(8):870-9. doi: 10.1158/2159-8290.CD-13-0015. Epub 2013 May 28.
2
LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence.LKB1 通过 FAK-LKB1 复合物抑制粘着斑激酶 (FAK) 信号转导，从而调节 FAK 位点成熟和定向持续性。
J Biol Chem. 2013 Jun 14;288(24):17663-74. doi: 10.1074/jbc.M112.444620. Epub 2013 May 1.
3
LKB1 and AMPK and the cancer-metabolism link - ten years after.LKB1 和 AMPK 与癌症代谢的联系——十年之后。
BMC Biol. 2013 Apr 15;11:36. doi: 10.1186/1741-7007-11-36.
4
LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.LKB1 失活决定了代谢药物苯乙双胍治疗非小细胞肺癌的疗效。
Cancer Cell. 2013 Feb 11;23(2):143-58. doi: 10.1016/j.ccr.2012.12.008. Epub 2013 Jan 24.
5
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.西利替尼联合多西他赛治疗 KRAS 突变型晚期非小细胞肺癌：一项随机、多中心、安慰剂对照、2 期研究。
Lancet Oncol. 2013 Jan;14(1):38-47. doi: 10.1016/S1470-2045(12)70489-8. Epub 2012 Nov 28.
6
Genomic landscape of non-small cell lung cancer in smokers and never-smokers.吸烟者和不吸烟者非小细胞肺癌的基因组图谱。
Cell. 2012 Sep 14;150(6):1121-34. doi: 10.1016/j.cell.2012.08.024.
7
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.大规模平行测序绘制肺腺癌特征图谱。
Cell. 2012 Sep 14;150(6):1107-20. doi: 10.1016/j.cell.2012.08.029.
8
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.一项小鼠肺癌联合临床试验确定了治疗反应的遗传修饰因子。
Nature. 2012 Mar 18;483(7391):613-7. doi: 10.1038/nature10937.
9
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors.综合基因组和蛋白质组学分析鉴定 Lkb1 缺陷型转移性肺肿瘤的靶点。
Cancer Cell. 2010 Jun 15;17(6):547-59. doi: 10.1016/j.ccr.2010.04.026.
10
Somatic LKB1 mutations promote cervical cancer progression.体细胞LKB1突变促进宫颈癌进展。
PLoS One. 2009;4(4):e5137. doi: 10.1371/journal.pone.0005137. Epub 2009 Apr 2.
Zotero 插件